Cite
HARVARD Citation
Jeffers, M. et al. (n.d.). 2341 Tumor genotyping and clonal evolution in KIT during regorafenib treatment in the phase III GRID study of regorafenib vs placebo in tyrosine kinase inhibitor (TKI)-refractory GIST. European journal of cancer. pp. S448-. [Online].